DENTSPLY SIRONA (XRAY) Upgraded at J P Morgan Chase & Co

J P Morgan Chase & Co upgraded shares of DENTSPLY SIRONA (NASDAQ:XRAY) from a neutral rating to an overweight rating in a research note published on Wednesday morning, MarketBeat.com reports. J P Morgan Chase & Co currently has $75.00 price target on the medical instruments supplier’s stock.

A number of other equities analysts have also issued reports on XRAY. HC Wainwright reissued a hold rating and set a $68.00 price target on shares of DENTSPLY SIRONA in a report on Thursday, December 7th. BidaskClub lowered DENTSPLY SIRONA from a strong-buy rating to a buy rating in a report on Saturday, December 2nd. Jefferies Group lowered their price target on DENTSPLY SIRONA from $72.00 to $66.00 and set a buy rating on the stock in a report on Wednesday, August 23rd. Zacks Investment Research raised DENTSPLY SIRONA from a strong sell rating to a hold rating in a report on Thursday, October 12th. Finally, Robert W. Baird set a $63.00 price target on DENTSPLY SIRONA and gave the stock a buy rating in a report on Thursday, October 19th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company’s stock. DENTSPLY SIRONA presently has a consensus rating of Buy and a consensus target price of $69.31.

Shares of DENTSPLY SIRONA (NASDAQ:XRAY) traded up $0.83 during mid-day trading on Wednesday, hitting $66.48. The company’s stock had a trading volume of 1,751,894 shares, compared to its average volume of 1,512,977. The stock has a market capitalization of $15,078.68, a price-to-earnings ratio of 26.16, a price-to-earnings-growth ratio of 2.60 and a beta of 1.31. DENTSPLY SIRONA has a 12 month low of $52.53 and a 12 month high of $68.98. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.59 and a current ratio of 2.32.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.04. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $978.99 million. DENTSPLY SIRONA had a positive return on equity of 7.56% and a negative net margin of 20.33%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.66 earnings per share. research analysts forecast that DENTSPLY SIRONA will post 2.65 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 12th. Shareholders of record on Friday, December 29th will be issued a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date of this dividend is Thursday, December 28th. DENTSPLY SIRONA’s dividend payout ratio is presently -10.09%.

In other DENTSPLY SIRONA news, insider Mark Thierer acquired 77,000 shares of the stock in a transaction on Monday, November 13th. The shares were bought at an average price of $66.04 per share, with a total value of $5,085,080.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Francis J. Lunger sold 8,900 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $65.90, for a total value of $586,510.00. The disclosure for this sale can be found here. 1.99% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in XRAY. Commonwealth Bank of Australia boosted its holdings in DENTSPLY SIRONA by 19.0% in the 2nd quarter. Commonwealth Bank of Australia now owns 1,626 shares of the medical instruments supplier’s stock valued at $104,000 after purchasing an additional 260 shares in the last quarter. Acrospire Investment Management LLC acquired a new stake in shares of DENTSPLY SIRONA during the 2nd quarter valued at approximately $113,000. Dupont Capital Management Corp acquired a new stake in shares of DENTSPLY SIRONA during the 2nd quarter valued at approximately $116,000. Massey Quick Simon & CO. LLC acquired a new stake in shares of DENTSPLY SIRONA during the 3rd quarter valued at approximately $124,000. Finally, Korea Investment CORP lifted its position in shares of DENTSPLY SIRONA by 139.9% during the 2nd quarter. Korea Investment CORP now owns 2,145 shares of the medical instruments supplier’s stock valued at $139,000 after acquiring an additional 1,251 shares during the period. 96.58% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “DENTSPLY SIRONA (XRAY) Upgraded at J P Morgan Chase & Co” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/12/16/dentsply-sirona-xray-upgraded-at-j-p-morgan-chase-co.html.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply